CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that enrollment and initial follow-up has been completed for the safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback